上海谊众2025年度归母净利润6413.2万元，同比增长819.42%

Core Viewpoint - Shanghai Yizhong (688091.SH) reported a significant increase in both revenue and net profit for the year 2025, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance directory [1] Financial Performance - The company achieved an operating revenue of 317 million yuan in 2025, representing a year-on-year growth of 82.72% [1] - The net profit attributable to the parent company reached 64.132 million yuan, marking a substantial year-on-year increase of 819.42% [1] Product Impact - The inclusion of paclitaxel polymer micelles in the national medical insurance directory significantly enhanced market access and the number of patients using the product, contributing to the overall revenue and profit growth for the company in 2025 [1]